{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:34Z","timestamp":1707525094781},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,11]]},"DOI":"10.7759\/cureus.37460","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T04:57:21Z","timestamp":1681275441000},"source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib as a Promising Treatment Option for Unresectable H\u00fcrthle Cell Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Parth  S","family":"Shirode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"D'cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sataksi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swayambhu","family":"Bhandarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S119980","article-title":"H\u00fcrthle cell carcinoma: current perspectives","volume":"9","author":"Ahmadi S","year":"2016","unstructured":"Ahmadi S, Stang M, Jiang XS, Sosa JA. H\u00fcrthle cell carcinoma: current perspectives. Onco Targets Ther. 2016, 9:6873-84. 10.2147\/OTT.S119980","journal-title":"Onco Targets Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0535","article-title":"The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland","volume":"22","author":"Nixon IJ","year":"2012","unstructured":"Nixon IJ, Whitcher MM, Palmer FL, et al.. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012, 22:884-9. 10.1089\/thy.2011.0535","journal-title":"Thyroid"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer","volume":"21","author":"Nair A","year":"2015","unstructured":"Nair A, Lemery SJ, Yang J, et al.. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res. 2015, 21:5205-8. 10.1158\/1078-0432.CCR-15-1377","journal-title":"Clin Cancer Res"},{"key":"ref4","unstructured":"Cancer of the Thyroid - Cancer Stat Facts. (n.d.). SEER. (2023). Accessed. 27\/02\/2023: https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.807","article-title":"Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization Classification","volume":"35","author":"Bai Y","year":"2020","unstructured":"Bai Y, Kakudo K, Jung CK. Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization Classification. Endocrinol Metab (Seoul). 2020, 35:696-715. 10.3803\/EnM.2020.807","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.129.2.207","article-title":"Survival and prognosis in H\u00fcrthle cell carcinoma of the thyroid gland","volume":"2003","author":"Bhattacharyya N","unstructured":"Bhattacharyya N. Survival and prognosis in H\u00fcrthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003:207-210. 10.1001\/archotol.129.2.207","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2179-3","article-title":"Treatment and outcome of 32 patients with distant metastases of H\u00fcrthle cell thyroid carcinoma: a single-institution experience","volume":"16","author":"Besic N","year":"2016","unstructured":"Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of H\u00fcrthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016, 16:162. 10.1186\/s12885-016-2179-3","journal-title":"BMC Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1634","article-title":"Clinical and molecular features of H\u00fcrthle cell carcinoma of the thyroid","volume":"100","author":"Chindris AM","year":"2015","unstructured":"Chindris AM, Casler JD, Bernet VJ, et al.. Clinical and molecular features of H\u00fcrthle cell carcinoma of the thyroid. J Clin Endocrinol Metab. 2015, 100:55-62. 10.1210\/jc.2014-1634","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti S","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, et al.. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019, 30:1856-83. 10.1093\/annonc\/mdz400","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al.. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016, 26:1-133. 10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"ref11","article-title":"Hurthle Cell Thyroid Carcinoma","author":"Fariduddin MM","year":"2023","unstructured":"Fariduddin MM, Syed W. Hurthle Cell Thyroid Carcinoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2023 Jan-."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.070","article-title":"Lenvatinib","volume":"40","year":"2017","unstructured":"Lenvatinib. Aust Prescr. 2017, 40.242-3. 10.18773\/austprescr.2017.070","journal-title":"Aust Prescr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger M","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al.. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015, 372:621-30. 10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130651-lenvatinib-as-a-promising-treatment-option-for-unresectable-hrthle-cell-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:38Z","timestamp":1707508718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130651-lenvatinib-as-a-promising-treatment-option-for-unresectable-hrthle-cell-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.37460","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}